Literature DB >> 20042712

Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue.

Louise C Pyle1, Jennifer C Fulton, Peter A Sloane, Kyle Backer, Marina Mazur, Jeevan Prasain, Stephen Barnes, J P Clancy, Steven M Rowe.   

Abstract

Therapies to correct the ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) folding defect require sensitive methods to detect channel activity in vivo. The β₂ adrenergic receptor agonists, which provide the CFTR stimuli commonly used in nasal potential difference assays, may not overcome the channel gating defects seen in ΔF508 CFTR after plasma membrane localization. In this study, we identify an agent, quercetin, that enhances the detection of surface ΔF508 CFTR, and is suitable for nasal perfusion. A screen of flavonoids in CFBE41o⁻ cells stably transduced with ΔF508 CFTR, corrected to the cell surface with low temperature growth, revealed that quercetin stimulated an increase in the short-circuit current. This increase was dose-dependent in both Fisher rat thyroid and CFBE41o⁻ cells. High concentrations inhibited Cl⁻ conductance. In CFBE41o⁻ airway cells, quercetin (20 μg/ml) activated ΔF508 CFTR, whereas the β₂ adrenergic receptor agonist isoproterenol did not. Quercetin had limited effects on cAMP levels, but did not produce detectable phosphorylation of the isolated CFTR R-domain, suggesting an activation independent of channel phosphorylation. When perfused in the nares of Cftr(+) mice, quercetin (20 μg/ml) produced a hyperpolarization of the potential difference that was absent in Cftr(-/-) mice. Finally, quercetin-induced, dose-dependent hyperpolarization of the nasal potential difference was also seen in normal human subjects. Quercetin activates CFTR-mediated anion transport in respiratory epithelia in vitro and in vivo, and may be useful in studies intended to detect the rescue of ΔF508 CFTR by nasal potential difference.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20042712      PMCID: PMC2970857          DOI: 10.1165/rcmb.2009-0281OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  53 in total

1.  A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs.

Authors:  L Al-Nakkash; S Hu; M Li; T C Hwang
Journal:  J Pharmacol Exp Ther       Date:  2001-02       Impact factor: 4.030

2.  A(2) adenosine receptors regulate CFTR through PKA and PLA(2).

Authors:  B R Cobb; F Ruiz; C M King; J Fortenberry; H Greer; T Kovacs; E J Sorscher; J P Clancy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-01       Impact factor: 5.464

3.  Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells.

Authors:  Marie E Egan; Judith Glöckner-Pagel; Catherine Ambrose; Paula A Cahill; Lamiko Pappoe; Naomi Balamuth; Edward Cho; Susan Canny; Carsten A Wagner; John Geibel; Michael J Caplan
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

4.  Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds.

Authors:  L J Galietta; M F Springsteel; M Eda; E J Niedzinski; K By; M J Haddadin; M J Kurth; M H Nantz; A S Verkman
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

5.  Effect of genistein on native epithelial tissue from normal individuals and CF patients and on ion channels expressed in Xenopus oocytes.

Authors:  M Mall; A Wissner; H H Seydewitz; M Hübner; J Kuehr; M Brandis; R Greger; K Kunzelmann
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

6.  Structural determinants for activation and block of CFTR-mediated chloride currents by apigenin.

Authors:  B Illek; M E Lizarzaburu; V Lee; M H Nantz; M J Kurth; H Fischer
Journal:  Am J Physiol Cell Physiol       Date:  2000-12       Impact factor: 4.249

7.  Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial.

Authors:  D A Shoskes; S I Zeitlin; A Shahed; J Rajfer
Journal:  Urology       Date:  1999-12       Impact factor: 2.649

Review 8.  Dietary flavonoids: bioavailability, metabolic effects, and safety.

Authors:  Julie A Ross; Christine M Kasum
Journal:  Annu Rev Nutr       Date:  2002-01-04       Impact factor: 11.848

9.  Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain.

Authors:  Mark F Springsteel; Luis J V Galietta; Tonghui Ma; Kolbot By; Gideon O Berger; Hong Yang; Christopher W Dicus; Wonken Choung; Chao Quan; Anang A Shelat; R Kiplin Guy; A S Verkman; Mark J Kurth; Michael H Nantz
Journal:  Bioorg Med Chem       Date:  2003-09-01       Impact factor: 3.641

10.  Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues.

Authors:  Agnes L-F Chan; Hui-Lin Huang; Hui-Chi Chien; Chi-Ming Chen; Chun-Nan Lin; Wun-Chang Ko
Journal:  Invest New Drugs       Date:  2008-02-09       Impact factor: 3.850

View more
  21 in total

1.  Hesperidin stimulates cystic fibrosis transmembrane conductance regulator-mediated chloride secretion and ciliary beat frequency in sinonasal epithelium.

Authors:  Christopher Azbell; Shaoyan Zhang; Daniel Skinner; James Fortenberry; Eric J Sorscher; Bradford A Woodworth
Journal:  Otolaryngol Head Neck Surg       Date:  2010-09       Impact factor: 3.497

2.  Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators.

Authors:  Louise C Pyle; Annette Ehrhardt; Lisa High Mitchell; Lijuan Fan; Aixia Ren; Anjaparavanda P Naren; Yao Li; J P Clancy; Graeme B Bolger; Eric J Sorscher; Steven M Rowe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-07-01       Impact factor: 5.464

3.  Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium.

Authors:  Nathan S Alexander; Neal Hatch; Shaoyan Zhang; Daniel Skinner; James Fortenberry; Eric J Sorscher; Bradford A Woodworth
Journal:  Laryngoscope       Date:  2011-04-07       Impact factor: 3.325

4.  Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: therapeutic implications for chronic rhinosinusitis.

Authors:  Shaoyan Zhang; Nicholas Smith; Daniel Schuster; Christopher Azbell; Eric J Sorscher; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2011 Sep-Oct       Impact factor: 2.467

5.  Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency.

Authors:  Bradford A Woodworth
Journal:  Laryngoscope       Date:  2015-05-06       Impact factor: 3.325

6.  Quercetin-induced Growth Inhibition in Human Bladder Cancer Cells Is Associated with an Increase in Ca-activated K Channels.

Authors:  Yangmi Kim; Wun-Jae Kim; Eun-Jong Cha
Journal:  Korean J Physiol Pharmacol       Date:  2011-10-31       Impact factor: 2.016

7.  DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers.

Authors:  S M Rowe; L C Pyle; A Jurkevante; K Varga; J Collawn; P A Sloane; B Woodworth; M Mazur; J Fulton; L Fan; Y Li; J Fortenberry; E J Sorscher; J P Clancy
Journal:  Pulm Pharmacol Ther       Date:  2010-03-10       Impact factor: 3.410

8.  Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.

Authors:  Steven M Rowe; Peter Sloane; Li Ping Tang; Kyle Backer; Marina Mazur; Jessica Buckley-Lanier; Igor Nudelman; Valery Belakhov; Zsuzsa Bebok; Erik Schwiebert; Timor Baasov; David M Bedwell
Journal:  J Mol Med (Berl)       Date:  2011-07-22       Impact factor: 4.599

9.  Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.

Authors:  Mark T Dransfield; Andrew M Wilhelm; Brian Flanagan; Clifford Courville; Sherry L Tidwell; S Vamsee Raju; Amit Gaggar; Chad Steele; Li Ping Tang; Bo Liu; Steven M Rowe
Journal:  Chest       Date:  2013-08       Impact factor: 9.410

10.  Transforming growth factor-β1 and cigarette smoke inhibit the ability of β2-agonists to enhance epithelial permeability.

Authors:  Hoshang J Unwalla; Pedro Ivonnet; John S Dennis; Gregory E Conner; Matthias Salathe
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.